EGFR and pancreatic neoplasm: For example, combination therapy using the EGFR monoclonal antibody cetuximab, or the EGFR tyrosine kinase inhibitor erlotinib, with an oncolytic HSV-1 have been explored with generated synergistic tumor killing by enhancing the anti-angiogenic effect in human colorectal cancers and human pancreatic cancers respectively [86, 87].